Pharmacokinetics of fudosteine in healthy volunteers

Yaoxue Xuebao

Volumn 40, Issue 10, 2005, Pages 945-949

  Ding, Li ^a   Yang, Jin ^a   Li, Rong Shan ^a   Zhou, Mei ^a   Shen, Jian Ping ^b   Zhang, Yin Di ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Fudosteine; HPLC FL; Pharmacokinetics

Indexed keywords

2-AMINO-3-(3-HYDROXYPROPYLTHIO)PROPIONIC ACID; CYSTINE; DRUG DERIVATIVE; FUDOSTEINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METHODOLOGY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; SEX FACTORS;

EID: 28444441994     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Komatsu H, Yamaguchi S, Komorita N, et al. Inhibition of endotoxin- and atigen-induced airway inflammation by fudosteine, a mucoactive agent [J]. Pulm Pharmacol Ther, 2005,18(2);121-127.
2. Takahashi K, Kai H, Mizuno H, et al. Effect of fudosteine, a new cysteine derivative, on mucociliary transport [J]. J Pharm Pharmacol, 2001,53(6):911-914.
3. Yang J, Wang GJ, Liu XQ, et al. Development of bioavailability program package 2.0 [J]. Chin J Clin Pharmacol, 2003,19(2): 125-127.